Previous 10 | Next 10 |
HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Recent research has identified processes that could lead to the growth of tumors. The research was conducted by a team at the University of Plymouth’s Brain Tumour Research Centre , led by Dr. Claudia Barros. This institution is focused on providing new understanding of certain groups ...
CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally The comp...
Figures show that brain cancer occurs in less than 1% of the population in America. At least one-third of individuals diagnosed with primary brain cancer tumors survive for at least five years. Those with glioblastoma, a common type of brain cancer, have about a 14% chance of living an addition...
Brain tumors, which affects thousands of individuals around the globe, can be diagnosed using various imaging techniques , including magnetic resonance imaging (MRI) and computed tomography (CT) scans. Some tumors cannot be diagnosed using these techniques, however, which makes it hard for them ...
A look at the top 10 most actives in the United States Remark Holdings Inc. (MARK) rose 264.4% to $1.25 on volume of 238,216,008 shares Advanced Micro Devices Inc. (AMD) fell 3.2% to $172.06 on volume of 122,265,677 shares Phunware Inc. (PHUN) fell 1.0% to $0.2893 on volume of 119,416,884...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best...
2024-01-30 02:19:13 ET More on CNS Pharmaceuticals Financial information for CNS Pharmaceuticals Read the full article on Seeking Alpha For further details see: CNS Pharmaceuticals prices $4M public offering
HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing ...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NYSE Market:
Scientists at Purdue University are trying to develop a new treatment for glioblastoma tumors. Glioblastoma is a type of cancer that originates in the spinal cord and/or brain. This cancer is fatal, with a median time of survival of 14 months. Conventional treatments for other cancers, includ...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced that its Chief Executive Officer John Climaco will present at the LSX World Congress 20...
Presentation on Monday, April 29 th at 4:15 PM (GMT+1) HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the ...